Celldex Therapeutics Announces Upcoming Data Presentations on CDX-1127 and
NEEDHAM, Mass. -- December 04, 2012
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced upcoming data
presentations on two of the Company’s fully human monoclonal antibody
programs—CDX-1127 and CDX-011.
Tibor Keler, PhD, Senior Vice President and Chief Scientific Officer, will
present a review of the CDX-1127 program at the IBC’s Antibody Engineering &
Antibody Therapeutics Meeting on Thursday, December 6, 2012 at 3:15 pm PT
(6:15 pm ET) at the Hilton San Diego Bayfront Hotel in San Diego, California.
The presentation will include a comprehensive review of preclinical results.
CDX-1127 binds CD27, an important co-stimulatory molecule on T cells, and is
designed to activate patients' immune cells against their cancer. The Company
is currently conducting a two-arm, multi-dose, Phase 1 study in patients with
selected malignant solid tumors or hematologic malignancies to determine a
Phase 2 dose for further development. The solid tumor arm is completing
accrual in the final dose cohort and, to date, has been well tolerated,
including at the highest dose level. The Company continues to enroll patients
in the hematologic arm and expects to complete enrollment in this arm in the
first half of 2013. Clinical results from both studies will be presented at a
future medical meeting.
Denise A. Yardley, MD, Senior Investigator in the Breast Cancer Research
Program at the Sarah Cannon Research Institute and a lead investigator in the
Phase 2b EMERGE study of CDX-011 in metastatic breast cancer, will present
mature results in a poster session at the San Antonio Breast Cancer Symposium
on Saturday, December 8, 2012 at 7:00 am CT (8:00 am ET) at the Henry B.
Gonzalez Convention Center in San Antonio, Texas. The Company anticipates the
presentation will include overall survival and duration of response data and
updated patient response and progression free survival data. The Company will
issue a press release at the time of the presentation and will make a copy of
the poster available on their website in the “Product Pipeline, Scientific
Presentations” section. CDX-011 targets and binds to GPNMB, a specific protein
expressed in breast cancer that promotes the migration, invasion and
metastasis of the disease. In May of 2012, the Company reported preliminary
positive results from the Phase 2b study, noting particularly impressive
response rates in patients with triple negative breast cancer who also have
high (≥ 25%) levels of GPNMB expression.
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy
company. Celldex has a pipeline of drug candidates in development for the
treatment of cancer and other difficult-to-treat diseases based on its
antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI
Platform is a complementary portfolio of monoclonal antibodies,
antibody-targeted vaccines and immunomodulators used in optimal combinations
to create novel disease-specific drug candidates. For more information, please
Safe Harbor Statement Under the Private Securities Litigation Reform Act of
1995: This release contains “forward-looking statements” made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of
1995, including those related to the Company’s strategic focus and the future
development and commercialization (by Celldex and others) of rindopepimut
(CDX-110), CDX-011, CDX-1135, CDX-1401, CDX-1127, CDX-301, Belinostat and
other products. Forward-looking statements reflect management's current
knowledge, assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations reflected in
such statements are reasonable, they give no assurance that such expectations
will prove to be correct and you should be aware that actual results could
differ materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties,
including, but not limited to, our limited cash reserves and our ability to
obtain additional capital on acceptable terms, or at all, including the
additional capital which will be necessary to complete the clinical trials
that we have initiated or plan to initiate; our ability to adapt APC Targeting
TechnologyTM to develop new, safe and effective vaccines against oncology and
infectious disease indications; our ability to successfully complete product
research and further development of our programs; the uncertainties inherent
in clinical testing; our limited experience in bringing programs through Phase
3 clinical trials; our ability to manage research and development efforts for
multiple products at varying stages of development; the timing, cost and
uncertainty of obtaining regulatory approvals; the failure of the market for
the Company's programs to continue to develop; our ability to protect the
Company’s intellectual property; the loss of any executive officers or key
personnel or consultants; competition; changes in the regulatory landscape or
the imposition of regulations that affect the Company’s products; and other
factors listed under “Risk Factors” in our annual report on Form 10-K.
All forward-looking statements are expressly qualified in their entirety by
this cautionary notice. You are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this release.
We have no obligation, and expressly disclaim any obligation, to update,
revise or correct any of the forward-looking statements, whether as a result
of new information, future events or otherwise.
Celldex Therapeutics, Inc.
Sarah Cavanaugh, 781-433-3161
Vice President of IR & Corp Comm
Brad Miles, 646-513-3125
Press spacebar to pause and continue. Press esc to stop.